雷珠单抗与康柏西普治疗白内障术后黄斑水肿的应用效果分析
Analysis of the Application Effects of Ranibizumab and Conbercept in the Treatment of Pseudophakic Cystoid Macular Edema
邓彤彤 1赵桂玲 2李素华1
作者信息
- 1. 湛江今日眼科医院眼科,广东湛江 524400
- 2. 广东医科大学附属医院眼科,广东湛江 524400
- 折叠
摘要
目的 比较雷珠单抗与康柏西普在治疗白内障术后黄斑水肿中的临床效果和安全性.方法 该研究为前瞻性随机对照研究,纳入126例白内障术后黄斑水肿患者,随机分为雷珠单抗组(n=63)和康柏西普组(n=63).两组患者分别接受 0.5mg/0.05mL雷珠单抗和康柏西普玻璃体腔内注射,治疗周期为3 个月.评估指标包括临床疗效、眼压、黄斑中心凹视网膜厚度、角膜神经纤维密度及长度,以及不良反应发生率.结果 两组在临床疗效方面无显著差异(P＞0.05).治疗后,两组眼压和黄斑中心凹视网膜厚度均显著下降(P＜0.001),组间差异无统计学意义.康柏西普组角膜神经纤维长度显著降低(P＜0.001),而雷珠单抗组未见明显变化,治疗后两组间存在显著差异(P＜0.001).两组不良反应发生率均较低,无统计学差异(P＞0.05).结论 雷珠单抗和康柏西普在治疗白内障术后黄斑水肿方面均显示了良好的临床效果和安全性.雷珠单抗可能在保护角膜神经纤维方面具有一定的优势,但仍需进一步研究验证.
Abstract
Objective To compare the clinical efficacy and safety of ranibizumab and conbercept in the treatment of Pseudophakic cystoid macular edema.Methods This prospective randomized controlled study included 126 patients with Pseudophakic cystoid macular edema,who were randomly assigned to either the ranibizumab group(n=63)or the conbercept group(n=63).Patients in the two groups received intravitreal injections of 0.5 mg/0.05 mL ranibizumab or conbercept respectively over a treatment period of 3 months.Evaluation indicators included clinical efficacy,intraocular pressure(IOP),central foveal retinal thickness(CFT),corneal nerve fiber density and length,as well as the incidence of adverse reactions.Results There was no significant difference in clinical efficacy between the two groups(P＞0.05).Both groups showed a significant reduction in IOP and CFT after treatment(P＜0.001),with no statistically significant differences between the groups.The conbercept group exhibited a significant decrease in corneal nerve fiber length(P＜0.001),whereas no significant changes were observed in the ranibizumab group;a significant difference between the groups was noted after treatment(P＜0.001).The incidence of adverse reactions was low in both groups,with no statistical difference(P＞0.05).Conclusions Both ranibizumab and conbercept demonstrate good clinical efficacy and safety in the treatment of Pseudophakic cystoid macular edema.Ranibizumab may offer advantages in preserving corneal nerve fibers;however,further research is needed to confirm this finding.
关键词
雷珠单抗/康柏西普/白内障术后黄斑水肿/临床效果/角膜神经纤维Key words
Ranibizumab/Conbercept/Pseudophakic Cystoid Macular Edema/Clinical Efficacy/Corneal Nerve Fibers引用本文复制引用
出版年
2024
NETL
NSTL
万方数据